应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
02359 药明康德
已收盘 10-02 16:08:09
210.000
-5.200
-2.42%
最高
211.400
最低
206.800
成交量
321.07万
今开
206.800
昨收
215.200
日振幅
2.14%
总市值
6,332亿
流通市值
1,136亿
总股本
30.15亿
成交额
6.72亿
换手率
0.59%
流通股本
5.41亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
异动解读｜药明康德盘中下跌3.07%，报208.4港元
行情直击 · 09:37
异动解读｜药明康德盘中下跌3.07%，报208.4港元
券商10月金股出炉，涉及医药、信息技术等领域，药明康德、中际旭创获推荐较多（名单）
第一财经 · 10-01 17:22
券商10月金股出炉，涉及医药、信息技术等领域，药明康德、中际旭创获推荐较多（名单）
小摩增持药明康德(02359)约200.73万股 每股作价约205.6港元
智通财经 · 09-30 19:25
小摩增持药明康德(02359)约200.73万股 每股作价约205.6港元
药明康德：赋能平台承载全球30多个国家数千名合作伙伴研发创新项目
证券之星 · 09-30 17:45
药明康德：赋能平台承载全球30多个国家数千名合作伙伴研发创新项目
9月30日药明康德现3726.66万元大宗交易
证券之星 · 09-30 17:33
9月30日药明康德现3726.66万元大宗交易
药明康德AH股午后均涨超5%
格隆汇 · 09-30 13:12
药明康德AH股午后均涨超5%
异动解读｜药明康德盘中上涨3.18%，贝莱德增持叠加员工持股计划获通过
行情直击 · 09-30 10:39
异动解读｜药明康德盘中上涨3.18%，贝莱德增持叠加员工持股计划获通过
药明康德（603259）披露2026年A股员工持股计划相关议案获临时股东会通过，9月29日股价下跌0.7%
证券之星 · 09-29 22:02
药明康德（603259）披露2026年A股员工持股计划相关议案获临时股东会通过，9月29日股价下跌0.7%
贝莱德增持药明康德(02359)约116.7万股 每股作价约179.83港元
智通财经 · 09-29
贝莱德增持药明康德(02359)约116.7万股 每股作价约179.83港元
药明康德（02359.HK）2026年首场临时股东会通过员工持股计划及章程修订
公告速递 · 09-29
药明康德（02359.HK）2026年首场临时股东会通过员工持股计划及章程修订
药明康德（02359）2026年首场临时股东会通过员工持股计划等四项议案
公告速递 · 09-29
药明康德（02359）2026年首场临时股东会通过员工持股计划等四项议案
药明康德临时股东会通过员工持股计划及章程修订 多项议案获高票通过
公告速递 · 09-29
药明康德临时股东会通过员工持股计划及章程修订 多项议案获高票通过
药明康德：摩根大通减持，好仓比例降至8.99%
港股披露 · 09-29
药明康德：摩根大通减持，好仓比例降至8.99%
药明康德：贝莱德增持，好仓比例升至5.16%
港股披露 · 09-29
药明康德：贝莱德增持，好仓比例升至5.16%
贝莱德：在药明康德H股的持股比例升至5.16%
格隆汇 · 09-29
贝莱德：在药明康德H股的持股比例升至5.16%
异动解读｜药明康德盘中上涨3.4%，可转债悉数转股消除稀释压力叠加机构增持
行情直击 · 09-29
异动解读｜药明康德盘中上涨3.4%，可转债悉数转股消除稀释压力叠加机构增持
药明康德：贝莱德减持，好仓比例降至4.96%
港股披露 · 09-28
药明康德：贝莱德减持，好仓比例降至4.96%
药明康德获FMR LLC增持46.73万股 每股作价约208.14港元
新浪港股 · 09-27
药明康德获FMR LLC增持46.73万股 每股作价约208.14港元
FMR LLC增持药明康德(02359)46.73万股 每股作价约208.14港元
智通财经 · 09-25
FMR LLC增持药明康德(02359)46.73万股 每股作价约208.14港元
药明康德：FMR LLC增持，好仓比例升至10.07%
港股披露 · 09-25
药明康德：FMR LLC增持，好仓比例升至10.07%
加载更多
公司概况
公司名称：
药明康德
所属市场：
SEHK
上市日期：
--
主营业务：
无锡药明康德新药开发股份有限公司是一家主要从事新药研发和生产服务业务的中国公司。该公司主要通过六个分部开展业务。化学业务分部主要从事提供新药研究、开发与生产服务。测试业务分部主要从事提供药品、医疗器械、体外诊断试剂服务。生物学业务分部主要从事提供药物发现及研究服务。高端治疗合同测试、研发与生产（CTDMO）业务分部主要从事为客户提供医疗产品工艺开发、生产和测试一体化服务。国内新药研发服务部分部主要从事为客户提供一体化新药研发服务。其他业务分部主要从事行政服务、销售原材料和销售废料业务。
发行价格：
--
{"stockData":{"symbol":"02359","market":"HK","secType":"STK","nameCN":"药明康德","latestPrice":210,"timestamp":1790928489005,"preClose":215.2,"halted":0,"volume":3210713,"delay":0,"changeRate":-0.02416356877323415,"floatShares":541000000,"shares":3015000000,"eps":7.738723811616265,"marketStatus":"已收盘","change":-5.2,"latestTime":"10-02 16:08:09","open":206.8,"high":211.4,"low":206.8,"amount":671782239,"amplitude":0.021375,"askPrice":210.2,"askSize":1000,"bidPrice":210,"bidSize":28800,"shortable":3,"etf":0,"ttmEps":8.62704735198757,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791163800000},"marketStatusCode":5,"adr":0,"listingDate":1544630400000,"exchange":"SEHK","adjPreClose":215.2,"dividendRate":0.011628,"openAndCloseTimeList":[[1790904600000,1790913600000],[1790917200000,1790928000000]],"volumeRatio":0.697013,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"WXA.HK","astockBrief":{"symbol":"603259","market":"SH","secType":"STK","nameCN":"药明康德","latestPrice":167.34,"timestamp":1790751600000,"preClose":160.66,"halted":0,"volume":44950900,"delay":0,"premium":"+7.19"},"impliedVol":0.5209,"impliedVolPercentile":0.8851},"requestUrl":"/m/hq/s/02359","defaultTab":"news","newsList":[{"id":"1102234736","title":"异动解读｜药明康德盘中下跌3.07%，报208.4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1102234736","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102234736?lang=zh_cn&edition=full","pubTime":"2026-10-02 09:37","pubTimestamp":1790905065,"startTime":"0","endTime":"0","summary":"10月2日，药明康德盘中下跌3.07%，报208.4港元/股，成交额1.75亿港元。药明康德所在的生命科学工具和服务行业中，板块个股普遍走低，其中药明生物跌3.48%，金斯瑞生物科技跌3.03%，英矽智能跌5.99%，药明合联跌4.51%，晶泰控股跌5.68%。公司是全球医药及生命科学行业一体化、端到端新药研发和生产服务提供商，业务涵盖化学药研发和生产、生物学研究、临床前测试和临床研发等领域，通过CRDMO模式服务全球客户。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672875510","title":"券商10月金股出炉，涉及医药、信息技术等领域，药明康德、中际旭创获推荐较多（名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2672875510","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2672875510?lang=zh_cn&edition=full","pubTime":"2026-10-01 17:22","pubTimestamp":1790846520,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！药明康德最受机构青睐，共入围了8家券商的推荐名单。截至发稿，逾10家券商公布了10月月度投资组合，涉及医药、信息技术、材料、消费等多个领域。哪些个股收获点名最多？据不完全统计，在各家券商的“金股”名单中，药明康德最受机构青睐，共入围了8家券商的推荐名单；其次是中际旭创，获得4家券商集体看好；海信视像、中国巨石均获得3家券商推荐。其中，药明康德在9月内涨幅最多，股价累计涨超8%，最新收盘价报167.34元；中国巨石9月震荡走低，月度累计下跌超10%，最新收盘价报39.41元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-10-01/doc-inittkrz1102637.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-10-01/doc-inittkrz1102637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91530","LU1719994722.HKD","BK0070","BK4544","LU0039217434.USD","LU2476274720.SGD","IE0032431581.USD","LU0164865239.USD","LU2148510915.USD","HK0000320264.USD","LU0052750758.USD","LU0348767384.USD","LU0417516738.SGD","LU0572944931.SGD","LU1146622755.USD","SG9999011746.SGD","LU0359202008.SGD","KCE","LU0700851271.USD","LU0231483743.USD","603259","02359","ARKG","BK0028","IE00BPRC5H50.USD","LU1046422090.SGD","BK1533","03308","HK0000306685.HKD","LU1064130708.USD","LU0708995583.HKD","SGXZ81163826.USD","BK0077","VGT","09939","159938","300308","BK4585","LU2213484517.USD","LU1997244956.HKD","IE00BYQNZ168.SGD","LU0082770016.SGD","LU0348827113.USD","159939","IE00B12V2V27.USD","IE00BYTNYN87.SGD","BK4588","LU2488822045.USD","LU0359201612.USD","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671020964","title":"小摩增持药明康德(02359)约200.73万股 每股作价约205.6港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671020964","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671020964?lang=zh_cn&edition=full","pubTime":"2026-09-30 19:25","pubTimestamp":1790767544,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月24日，小摩增持药明康德(02359)200.7296万股，每股作价205.5962港元，总金额约为4.13亿港元。增持后最新持股数目约为5253.64万股，持股比例为9.35%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502822.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["UYG","BK4588","IYG","IE00BBT3K403.USD","LU2488822045.USD","LU2244417387.USD","LU1261432733.SGD","IE00BJTD4N35.SGD","IYF","LU0700851271.USD","IXG","LU1988902786.USD","FTXO","LU0251132253.USD","LU2106854487.HKD","IE00BKVL7J92.USD","LU0106261372.USD","LU0820562030.AUD","LU2054465674.USD","BK4504","02359","LU1084165304.USD","XLF","EWH","LU2357305700.SGD","FNCL","IE000F7OJYX1.SGD","LU0327786744.USD","JPMO","LU2237443622.USD","VFH","LU1914381329.SGD","LU0211326839.USD","LU0048584097.USD","LU1496350502.SGD","LU2242649171.HKD","603259","LU0345769631.USD","LU0611395673.USD","KBWB","LU2381873111.SGD","TFNS","TRUF","LU1363072403.SGD","JPO","LU1366333091.USD","BK1141","LU2756315664.SGD","LU0417517546.SGD","LU0787776722.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671270097","title":"药明康德：赋能平台承载全球30多个国家数千名合作伙伴研发创新项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2671270097","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671270097?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:45","pubTimestamp":1790761521,"startTime":"0","endTime":"0","summary":"证券之星消息，药明康德(603259)09月30日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司的客户有哪些大型药企，劳烦请举例说明，谢谢。药明康德回复：您好，感谢您对公司的关注。公司是全球医药及生命科学行业值得信赖的合作伙伴和重要贡献者，致力于通过提供一体化、端到端的新药研发和生产服务，推动全球医药健康创新。公司尊重客户商业机密，不评论任何具体客户情况。目前，公司的赋能平台正承载着来自全球30多个国家的数千名合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。相关 ETF责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000028584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0456842615.SGD","LU0708995583.HKD","LU0611395673.USD","LU0052750758.USD","LU0348767384.USD","LU0469268626.HKD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU1046422090.SGD","LU1997245177.USD","LU1934453819.USD","LU1997245094.SGD","BK0216","LU2495084118.USD","LU1997244956.HKD","LU1979443071.USD","LU2045819591.USD","LU1303224171.USD","LU2242644610.SGD","LU0700851271.USD","LU2328871848.SGD","BK1141","LU1808992512.USD","LU0320764599.SGD","LU2488822045.USD","IE00BPRC5H50.USD","LU0327786744.USD","LU1969619763.USD","LU1251922891.USD","LU1770034418.SGD","BK1576","603259","BK1583","LU1719994722.HKD","02359","LU0348766576.USD","LU2125910500.SGD","LU0572944931.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671270628","title":"9月30日药明康德现3726.66万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2671270628","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671270628?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:33","pubTimestamp":1790760839,"startTime":"0","endTime":"0","summary":"证券之星消息，9月30日药明康德发生大宗交易，交易数据如下：近三个月该股共发生19笔大宗交易，合计成交2.03万手。该股近期无解禁股上市。截至2026年9月30日收盘，药明康德(603259)报收于167.34元，上涨4.16%，换手率1.82%，成交量44.95万手，成交额74.42亿元。该股最近90天内共有30家机构给出评级，买入评级27家，增持评级3家；过去90天内机构目标均价为197.88。本文数据来源于上海证券交易所大宗交易信息披露，仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000027877.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603259","LU1979443071.USD","LU2328871848.SGD","LU1934453819.USD","IE00B543WZ88.USD","LU1251922891.USD","LU2242644610.SGD","IE00B5MMRT66.SGD","LU1770034418.SGD","LU2125910500.SGD","LU0456842615.SGD","LU1997244956.HKD","LU2495084118.USD","LU0700851271.USD","LU1997245094.SGD","LU1719994722.HKD","LU0348766576.USD","LU0611395673.USD","IE00BPRC5H50.USD","LU0572944931.SGD","LU2488822045.USD","LU1997245177.USD","LU0708995583.HKD","BK1576","LU1969619763.USD","LU0469268626.HKD","LU0348767384.USD","LU1303224171.USD","LU0320764599.SGD","BK1583","LU0327786744.USD","BK0216","LU1046422090.SGD","LU0052750758.USD","LU2045819591.USD","02359","LU1808992512.USD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671607220","title":"药明康德AH股午后均涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671607220","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671607220?lang=zh_cn&edition=full","pubTime":"2026-09-30 13:12","pubTimestamp":1790745132,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0348766576.USD","LU2495084118.USD","LU0611395673.USD","LU0456842615.SGD","LU0052750758.USD","LU2242644610.SGD","LU1303224171.USD","LU2045819591.USD","BK1583","LU1251922891.USD","BK0216","LU1770034418.SGD","LU1997244956.HKD","LU1934453819.USD","LU1969619763.USD","BK1576","IE00BPRC5H50.USD","LU1046422090.SGD","LU0348767384.USD","LU1997245094.SGD","LU1979443071.USD","603259","LU1997245177.USD","LU2328871848.SGD","LU0320764599.SGD","02359","LU0708995583.HKD","BK1141","IE00B543WZ88.USD","LU2125910500.SGD","LU0327786744.USD","LU1808992512.USD","LU0700851271.USD","LU2488822045.USD","LU1719994722.HKD","IE00B5MMRT66.SGD","LU0572944931.SGD","LU0469268626.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153280937","title":"异动解读｜药明康德盘中上涨3.18%，贝莱德增持叠加员工持股计划获通过","url":"https://stock-news.laohu8.com/highlight/detail?id=1153280937","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153280937?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:39","pubTimestamp":1790735948,"startTime":"0","endTime":"0","summary":"9月30日，药明康德盘中上涨3.18%，报214.4港元，成交额3.61亿港元。消息面上，贝莱德于9月24日以每股约179.83港元在场内增持约116.7万股，涉资约2.1亿港元，持股比例由4.96%升至5.16%。此外，公司9月29日召开临时股东大会，员工持股计划及章程修订等四项议案全部高票通过，合计57.33%有表决权股份参与投票。此前公司人民币67.8亿元零息可转债已悉数转换为H股，稀释压力彻底消除。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明康德获贝莱德增持，员工持股计划高票通过","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671210149","title":"药明康德（603259）披露2026年A股员工持股计划相关议案获临时股东会通过，9月29日股价下跌0.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671210149","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671210149?lang=zh_cn&edition=full","pubTime":"2026-09-29 22:02","pubTimestamp":1790690531,"startTime":"0","endTime":"0","summary":"截至2026年9月29日收盘，药明康德报收于160.66元，较前一交易日下跌0.7%，最新总市值为4875.88亿元。该股当日开盘161.81元，最高166.68元，最低159.47元，成交额达49.28亿元，换手率为1.23%。所有议案均获通过，无否决议案。会议由董事长Ge Li（李革）博士主持，表决方式符合《公司法》及《公司章程》规定。国浩律师（上海）事务所对本次会议进行了见证并出具法律意见书，认为会议召集、召开程序合法，决议合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900039544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","LU2242644610.SGD","LU0348766576.USD","BK1583","02827","LU0700851271.USD","LU1303224171.USD","LU1997244956.HKD","02823","BK1576","82823","02359","83188","03188","LU2125910500.SGD","07233","82822","399300","BK1610","LU0611395673.USD","LU1934453819.USD","LU1770034418.SGD","02822","LU1808992512.USD","BK1141","LU1046422090.SGD","603259","LU2495084118.USD","03130","LU1997245094.SGD","83130","LU0469268626.HKD","02843","82843","IE00B543WZ88.USD","LU1251922891.USD","02846","82846","159982","LU1969619763.USD","LU0320764599.SGD","LU0052750758.USD","LU2045819591.USD","LU0348767384.USD","LU1997245177.USD","LU2488822045.USD","LU1719994722.HKD","LU0708995583.HKD","LU0572944931.SGD","LU1979443071.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671219598","title":"贝莱德增持药明康德(02359)约116.7万股 每股作价约179.83港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671219598","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671219598?lang=zh_cn&edition=full","pubTime":"2026-09-29 19:20","pubTimestamp":1790680839,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月24日，贝莱德增持药明康德(02359)116.7015万股，每股作价179.8314港元，总金额约为2.1亿港元。增持后最新持股数目约为2899.81万股，最新持股比例为5.16%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0611395673.USD","LU1303224171.USD","LU2495084118.USD","BK1576","BK0216","LU0572944931.SGD","603259","LU0456842615.SGD","LU2045819591.USD","02359","LU2488822045.USD","LU0348766576.USD","LU2125910500.SGD","LU1969619763.USD","LU1979443071.USD","LU1997244956.HKD","EWH","LU0320764599.SGD","LU1808992512.USD","IE00B5MMRT66.SGD","BK1141","LU0348767384.USD","LU1997245094.SGD","LU2328871848.SGD","LU0327786744.USD","BK1583","LU2242644610.SGD","LU0052750758.USD","LU1997245177.USD","IE00B543WZ88.USD","LU0708995583.HKD","LU0469268626.HKD","LU0700851271.USD","LU1770034418.SGD","LU1251922891.USD","LU1719994722.HKD","LU1934453819.USD","LU1046422090.SGD","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143764075","title":"药明康德（02359.HK）2026年首场临时股东会通过员工持股计划及章程修订","url":"https://stock-news.laohu8.com/highlight/detail?id=1143764075","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143764075?lang=zh_cn&edition=full","pubTime":"2026-09-29 18:22","pubTimestamp":1790677329,"startTime":"0","endTime":"0","summary":"无锡药明康德新药开发股份有限公司9月29日召开2026年第一次临时股东大会。共4,241名股东及股东代表出席，合计代表股份1,722,821,529股，占公司有表决权股份总数的57.3308%。上海国浩律师事务所对本次股东大会的召集、召开及表决过程进行了现场见证，并出具法律意见书，确认会议程序、人员资格及表决结果合法有效。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100372407","title":"药明康德（02359）2026年首场临时股东会通过员工持股计划等四项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=1100372407","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100372407?lang=zh_cn&edition=full","pubTime":"2026-09-29 18:21","pubTimestamp":1790677319,"startTime":"0","endTime":"0","summary":"无锡药明康德新药开发股份有限公司于2026年9月29日在上海外高桥喜来登酒店召开2026年第一次临时股东大会，会议由董事长李革博士主持，以现场投票及网络投票方式进行。会上共有4,241名股东及股东代理人出席，其中A股股东4,239名，H股股东2名；合计行使表决权股份17.23亿股，占公司有表决权股份总数的57.3308%。公司表示，员工代表大会已审议并通过上述员工持股计划及管理办法。根据股东大会表决结果，相关议案全部获准通过。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109303917","title":"药明康德临时股东会通过员工持股计划及章程修订 多项议案获高票通过","url":"https://stock-news.laohu8.com/highlight/detail?id=1109303917","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109303917?lang=zh_cn&edition=full","pubTime":"2026-09-29 17:45","pubTimestamp":1790675156,"startTime":"0","endTime":"0","summary":"2026年9月29日，无锡药明康德新药开发股份有限公司公布临时股东大会表决结果。大会以现场投票及网络投票方式审议的全部议案均获高比例通过，并同步完成公司章程修订。本次会议共有4,241名具表决权的股东及授权代表出席或通过网络投票，合计持股1,722,821,529股，占公司有表决权股份总数的57.3308%。其中，A股股东及授权代表4,239名，持股1,407,622,288股，占46.8418%；H股股东及授权代表2名，持股315,199,241股，占10.4890%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194472197","title":"药明康德：摩根大通减持，好仓比例降至8.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=1194472197","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194472197?lang=zh_cn&edition=full","pubTime":"2026-09-29 17:25","pubTimestamp":1790673929,"startTime":"0","endTime":"0","summary":"摩根大通于2026年9月23日在场外以每股均价208.03港元出售232.78万股药明康德（02359）H股，涉资约4.84亿港元，该笔交易因不再持有相关股份的保证权益而触发，属场外交易（代价性质：现金），未经联交所公开市场撮合，不属二级市场直接买卖。摩根大通此次减持前持有药明康德好仓5285.69万股，占比9.43%；减持后持股量为5052.91万股，好仓比例降至8.99%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185530123","title":"药明康德：贝莱德增持，好仓比例升至5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1185530123","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185530123?lang=zh_cn&edition=full","pubTime":"2026-09-29 17:24","pubTimestamp":1790673885,"startTime":"0","endTime":"0","summary":"贝莱德于2026年9月24日在联交所场内以每股均价179.8314港元买入药明康德股份116.70万股，涉资约2.10亿港元，属场内主动交易，即在二级市场直接买卖股份。贝莱德此次增持前持有药明康德好仓2783.10万股，占比4.96%；增持后持股量为2899.81万股，好仓比例升至5.16%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671205297","title":"贝莱德：在药明康德H股的持股比例升至5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671205297","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671205297?lang=zh_cn&edition=full","pubTime":"2026-09-29 17:10","pubTimestamp":1790673046,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0348766576.USD","BK1583","LU0348767384.USD","LU2045819591.USD","LU1046422090.SGD","LU0052750758.USD","02359","LU0572944931.SGD","LU2242644610.SGD","LU0320764599.SGD","LU0327786744.USD","LU0708995583.HKD","BK1141","BK1576","LU2125910500.SGD","LU0469268626.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195233186","title":"异动解读｜药明康德盘中上涨3.4%，可转债悉数转股消除稀释压力叠加机构增持","url":"https://stock-news.laohu8.com/highlight/detail?id=1195233186","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195233186?lang=zh_cn&edition=full","pubTime":"2026-09-29 09:54","pubTimestamp":1790646894,"startTime":"0","endTime":"0","summary":"9月29日，药明康德盘中上涨3.4%，报213.0港元，成交额1.5亿港元。消息面上，公司此前公告人民币67.8亿元于2027年到期的美元结算零息可转换债券已悉数转换为H股，维也纳证券交易所上市地位已于9月25日正式撤销，意味着可转债稀释压力彻底消除。与此同时，FMR LLC于9月22日以每股约208.14港元增持46.73万股，持股比例升至10.07%，涉资约9726万港元。同行业个股同步走强，药明生物涨4.03%、英矽智能涨4.09%、晶泰控股涨2.75%，板块整体情绪偏暖。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明康德盘中上扬，可转债转股消除压力","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146823774","title":"药明康德：贝莱德减持，好仓比例降至4.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=1146823774","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146823774?lang=zh_cn&edition=full","pubTime":"2026-09-28 17:22","pubTimestamp":1790587378,"startTime":"0","endTime":"0","summary":"贝莱德于2026年9月23日以场外交易方式（代价性质：非现金资产）解除其持有的药明康德H股保证权益，涉及211.15万股，属场外交易，未经联交所公开市场撮合，不属二级市场直接买卖。贝莱德此次减持前持有药明康德好仓2994.02万股，占比5.34%；减持后持股量为2782.88万股，好仓比例降至4.96%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670704124","title":"药明康德获FMR LLC增持46.73万股 每股作价约208.14港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670704124","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670704124?lang=zh_cn&edition=full","pubTime":"2026-09-27 12:21","pubTimestamp":1790482860,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端香港联交所最新数据显示，9月22日，FMR LLC增持药明康德（02359）46.73万股，每股作价208.1367港元，总金额约为9726.23万港元。增持后最新持股数目约为5641.78万股，持股比例为10.07%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-09-27/doc-initftkp4852021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2242644610.SGD","LU2488822045.USD","LU0611395673.USD","LU0456842615.SGD","LU1997245177.USD","02359","BK1576","LU1934453819.USD","BK0216","LU0469268626.HKD","LU1997245094.SGD","LU2495084118.USD","BK1141","LU0052750758.USD","LU1046422090.SGD","BK1583","LU2125910500.SGD","603259","LU1251922891.USD","LU1719994722.HKD","LU0708995583.HKD","LU0348767384.USD","LU0572944931.SGD","LU0327786744.USD","LU0348766576.USD","LU1997244956.HKD","LU1770034418.SGD","LU1969619763.USD","LU1808992512.USD","EWH","LU0700851271.USD","IE00B5MMRT66.SGD","LU1303224171.USD","IE00BPRC5H50.USD","LU1979443071.USD","LU0320764599.SGD","IE00B543WZ88.USD","LU2328871848.SGD","LU2045819591.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670421674","title":"FMR LLC增持药明康德(02359)46.73万股 每股作价约208.14港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670421674","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670421674?lang=zh_cn&edition=full","pubTime":"2026-09-25 19:16","pubTimestamp":1790334962,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月22日，FMR LLC增持药明康德(02359)46.73万股，每股作价208.1367港元，总金额约为9726.23万港元。增持后最新持股数目约为5641.78万股，持股比例为10.07%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","IE00B5MMRT66.SGD","603259","LU0348766576.USD","LU0708995583.HKD","LU1770034418.SGD","LU0572944931.SGD","LU0456842615.SGD","02359","LU1979443071.USD","LU1046422090.SGD","LU0320764599.SGD","LU1997245094.SGD","LU2495084118.USD","LU1251922891.USD","LU2045819591.USD","LU0611395673.USD","BK0216","LU0348767384.USD","LU0469268626.HKD","LU0052750758.USD","LU1808992512.USD","LU2328871848.SGD","LU1719994722.HKD","LU1997244956.HKD","LU2242644610.SGD","LU1303224171.USD","LU2125910500.SGD","EWH","IE00BPRC5H50.USD","LU0700851271.USD","LU2488822045.USD","LU0327786744.USD","LU1969619763.USD","BK1576","IE00B543WZ88.USD","BK1141","LU1934453819.USD","LU1997245177.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167005723","title":"药明康德：FMR LLC增持，好仓比例升至10.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1167005723","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167005723?lang=zh_cn&edition=full","pubTime":"2026-09-25 17:24","pubTimestamp":1790328273,"startTime":"0","endTime":"0","summary":"FMR LLC于2026年9月22日在联交所场内以每股均价208.1367港元买入药明康德（02359）H股46.73万股，涉资约9726.23万港元，属场内主动交易，即在二级市场直接买卖股份。FMR LLC此次增持前持有药明康德好仓5595.05万股，占比9.98%；增持后持股量为5641.78万股，好仓比例升至10.07%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.wuxiapptec.com.cn","stockEarnings":[{"period":"1week","weight":0.0366},{"period":"1month","weight":0.1368},{"period":"3month","weight":0.4125},{"period":"6month","weight":0.7508},{"period":"1year","weight":0.8422},{"period":"ytd","weight":1.2155}],"compareEarnings":[{"period":"1week","weight":-0.0089},{"period":"1month","weight":-0.0373},{"period":"3month","weight":0.0676},{"period":"6month","weight":-0.02},{"period":"1year","weight":-0.0835},{"period":"ytd","weight":-0.0397}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"无锡药明康德新药开发股份有限公司是一家主要从事新药研发和生产服务业务的中国公司。该公司主要通过六个分部开展业务。化学业务分部主要从事提供新药研究、开发与生产服务。测试业务分部主要从事提供药品、医疗器械、体外诊断试剂服务。生物学业务分部主要从事提供药物发现及研究服务。高端治疗合同测试、研发与生产（CTDMO）业务分部主要从事为客户提供医疗产品工艺开发、生产和测试一体化服务。国内新药研发服务部分部主要从事为客户提供一体化新药研发服务。其他业务分部主要从事行政服务、销售原材料和销售废料业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.026729},{"month":2,"riseRate":0.5,"avgChangeRate":0.002973},{"month":3,"riseRate":0.375,"avgChangeRate":-0.010735},{"month":4,"riseRate":0.5,"avgChangeRate":0.006501},{"month":5,"riseRate":0.375,"avgChangeRate":-0.004537},{"month":6,"riseRate":0.75,"avgChangeRate":0.089541},{"month":7,"riseRate":0.75,"avgChangeRate":0.092416},{"month":8,"riseRate":0.625,"avgChangeRate":0.059692},{"month":9,"riseRate":0.625,"avgChangeRate":0.094161},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.002334},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.00294},{"month":12,"riseRate":0.571429,"avgChangeRate":0.03824}],"exchange":"SEHK","name":"药明康德","nameEN":"WUXI APPTEC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明康德(02359)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明康德(02359)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明康德,02359,药明康德股票,药明康德股票老虎,药明康德股票老虎国际,药明康德行情,药明康德股票行情,药明康德股价,药明康德股市,药明康德股票价格,药明康德股票交易,药明康德股票购买,药明康德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明康德(02359)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明康德(02359)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}